Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

7 Jun 2011

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo.

6 Jun 2011

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.

6 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

In the first large trial of its kind in the United States, researchers have shown that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer.

10 May 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, announced the National Cancer Institute (NCI) will sponsor a multi-center phase 2 study of Syndax's lead product entinostat, a novel inhibitor of histone deacetylases (HDAC), and anastrozole, an aromatase inhibitor, in postmenopausal women with operable triple negative breast cancer to evaluate biomarkers and surrogates for response.

2 Mar 2011

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

13 Dec 2010

Higher co-payments lead to early discontinuation of life-saving therapy for breast cancer

A higher prescription co-payment, especially among older women, is associated with both early discontinuation and incomplete use of adjuvant aromatase inhibitor therapy, a life-saving therapy for women with hormone sensitive early stage breast cancer.

13 Dec 2010

Simple fingertip test may help evaluate risk for CTS in breast cancer patients

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. The information is embargoed for the time of presentation at the symposium.

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been previously treated with an aromatase inhibitor (AI) delays disease progression compared to tamoxifen alone. These results were presented today at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium in San Antonio, Texas.

10 Dec 2010

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

10 Dec 2010

Breast cancer patients more likely to have joint pain from taking AIs: Study

Breast cancer patients are more likely to have joint pain from taking aromatase inhibitors if they have advanced stage cancer, according to a study presented at the American College of Rheumatology's annual meeting, held Nov. 7-11, in Atlanta. The study is one of the first to identify factors that increase the likelihood that a patient will suffer joint pain from AI therapy.

10 Nov 2010

Special Surgery investigators to present future of clinical care at ACR annual meeting

Hospital for Special Surgery physicians who focus on lupus, scleroderma and related conditions are traveling from New York City to Atlanta this week to share their recent findings at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

10 Nov 2010

Aromatase inhibitors increase side effects in women undergoing breast cancer therapy

Women being treated for breast cancer with aromatase inhibitors may experience extremely low estrogen levels resulting in a wide variety of side effects that a typical postmenopausal woman without cancer may not experience.

10 Nov 2010

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

A new study suggests joint complaints attributed to aromatase inhibitors (AI), popular breast cancer drugs, are not associated with inflammatory arthritis or autoimmune disease. Because of that, researchers say women who were primarily concerned about the threat of arthritis should be encouraged to continue taking the medication. The findings of the study will be presented Tuesday, Nov. 9 at the 74th Annual Scientific Meeting of the American College of Rheumatology in Atlanta, Georgia

9 Nov 2010

Amgen wins Scrip Best New Drug award for Prolia

Amgen is pleased to announce that it has won the Best New Drug award for Prolia™ (denosumab), a novel treatment approved in the United States (U.S.) for women with postmenopausal osteoporosis at high risk for fracture, at the 2010 Scrip Awards ceremony Nov. 4 in London. Named one of TIME's Top 10 Medical Breakthroughs of 2009, Prolia is the first treatment specifically designed to target osteoclasts, the cells that break down bone.

8 Nov 2010

New radiotracer application may advance understanding of estrogen-related diseases

A study at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory has demonstrated that a molecule "tagged" with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estrogen, in the human brain. The research, published in the November issue of Synapse, also uncovered that the regions of the brain where aromatase is concentrated may be unique to humans.

4 Nov 2010

Aromatase Inhibitor News and Research

APP to commence marketing Letrozole Tablets for breast cancer in the U.S.

NCIC CTG's exemestane clinical trial data on breast cancer presented at ASCO 2011

Exemestane reduces risk of breast cancer in high-risk, postmenopausal women

Researcher to evaluate new approach for treatment of triple-negative breast cancer

Treatment with estrogen-lowering drugs shrinks tumors and reduces mastectomy rates in breast cancer patients

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

NCI sponsors multi-center phase 2 study of entinostat-anastrozole combination in triple negative breast cancer

Syndax reports promising results from entinostat preclinical studies in breast cancer

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Higher co-payments lead to early discontinuation of life-saving therapy for breast cancer

Simple fingertip test may help evaluate risk for CTS in breast cancer patients

Depression drug appears effective in reducing pain associated with breast cancer treatment

Everolimus plus tamoxifen delays disease progression in HR+/HER2- metastatic breast cancer

Aromatase inhibitors raise risk of cardiovascular disease in postmenopausal breast cancer patients

Breast cancer patients more likely to have joint pain from taking AIs: Study

Special Surgery investigators to present future of clinical care at ACR annual meeting

Aromatase inhibitors increase side effects in women undergoing breast cancer therapy

Joint complaints attributed to breast cancer drugs not linked with inflammatory arthritis or autoimmune disease

Amgen wins Scrip Best New Drug award for Prolia

New radiotracer application may advance understanding of estrogen-related diseases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News